Lapatinib, a small molecule inhibitor of the family of Human Epidermal Growth Factor Receptor 1 (HER1 or EGFR) and HER2 oncogenic receptor tyrosine kinases, is approved for the treatment of advanced stage HER2-overexpressing (HER2+) breast cancers. The gene discussed is EGFR; the disease is breast cancer.